- Imugene Limited (ASX:IMU) has recently appointed Dr Monil Shah as the Chief Business Officer of the Company.
- Dr Shah will lead Imugene’s global business development and partnering activities and support the Company’s clinical development.
- The appointment of Dr Shah has added deep experience to Imugene’s management team.
Clinical-stage immuno-oncology firm Imugene Limited (ASX:IMU) has recently announced the appointment of its new Chief Business Officer (CBO). The Company notified that it has hired Dr Monil Shah, PharmD, MBA, as the CBO of Imugene and a member of its executive management team.
Following the key update, Imugene shares rallied by over 6 per cent to AU$0.330 as of 1:16 PM AEST.
Dr Shah has received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from New Jersey-based Rutgers University. He will lead Imugene’s global business development and partnering activities and support the Company’s clinical development.
The appointment of Dr Shah has added deep experience to Imugene’s management team, which includes several international cancer experts. These experts hold extensive experience in developing novel cancer therapies, with many approved for marketing and sale for global markets.
Imugene’s vision is to improve as well as transform the treatment of cancer and the lives of the millions of cancer patients who need effective treatments.
Dr Shah’s rich experience in oncology drug development
Dr Monil Shah holds more than 20 years of biotechnology and pharmaceutical industry experience in oncology drug development.
His last appointment was as Chief Development Officer at US-based WindMIL Therapeutics, responsible for the cell therapy platform. He has also served as the Chief Operating Officer of Brooklyn ImmunoTherapeutics, leading cytokine drug development for oncology patients. Before that, he worked as the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb, responsible for checkpoint inhibitor development programs.
Dr Shah has also served as the Founder and Head of Clinical Development and Operations at Ventrus Biosciences before its merger with Assembly Biosciences. Before Ventrus, he led the Clinical Portfolio and Strategic Planning function and solid tumour development programs at Celgene, in addition to Oncology Development and Operations activities at Novacea and Fibrogen. He commenced his career at Novartis in the Oncology Early Development Group before joining the Medical Sciences Group at Amgen.
Dr Shah enthusiastic to join Imugene
Dr Shah is enthusiastic about joining a wonderful team of experts at Imugene that boasts a strong pipeline of innovative immunotherapy vaccines and oncolytic viruses, comprising the revolutionary CD19-CF33 onCARlyticsTM having the potential to turn CAR T therapy against solid tumours.
Imugene recently entered into a licensing agreement with the City of Hope for the patents covering novel combination immunotherapy - onCARlyticsTM, which makes the treatment of solid tumours viable by CAR T drugs. The Company anticipates the commencement of the onCARlyticsTM Phase 1 study in 2022.
Imugene’s Executive Chairman, Mr Paul Hopper, is also pleased to welcome the new CBO to the Company. As per Mr Hopper, Dr Shah adds a critical business development capability to the Company’s senior management team. Dr Shah, along with Imugene’s team, will continue to drive towards safer and better treatments for the benefit of patients.